Xolinic 4 mg contains Zoledronic Acid, a potent third-generation bisphosphonate that inhibits osteoclast-mediated bone resorption. It is widely used in oncology to protect bone health and prevent complications associated with cancer spread to bones.

🔬 Mechanism of Action

Zoledronic Acid binds strongly to bone tissue and suppresses osteoclast activity. As a result, it:

• Reduces bone destruction
• Decreases risk of fractures
• Lowers high blood calcium levels
• Helps relieve bone pain

By slowing bone breakdown, it improves skeletal stability in patients with advanced cancers.

💊 Indications

Xolinic 4 mg is indicated for:

• Bone metastases from solid tumors (such as breast, prostate, and lung cancer)
• Multiple Myeloma
• Hypercalcemia of Malignancy (HCM)
• Prevention of skeletal-related events in advanced cancer patients

📌 Key Features of Xolinic 4 mg

• Strength: 4 mg
• Dosage Form: Intravenous infusion
• Therapeutic Class: Bisphosphonate
• Administration: Given via IV infusion over at least 15 minutes in a clinical setting
• Monitoring: Kidney function tests and serum calcium levels required prior to each dose

⚕️ Benefits of Zoledronic Acid

• Protects bone integrity
• Reduces skeletal complications
• Controls elevated calcium levels effectively
• Long duration of action

⚠️ Precautions

• Renal function must be assessed before each dose
• Adequate hydration required before infusion
• Risk of hypocalcemia; calcium and vitamin D supplementation may be recommended
• Rare risk of osteonecrosis of the jaw (ONJ); dental evaluation advised before treatment
• Use under oncologist supervision

Xolinic 4 mg (Zoledronic Acid Injection) is an essential supportive oncology therapy that helps maintain bone strength, reduce complications, and improve quality of life in patients with cancer-related bone involvement.